{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:39:35Z","timestamp":1782725975706,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,3]],"date-time":"2016-09-03T00:00:00Z","timestamp":1472860800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s11239-016-1417-5","type":"journal-article","created":{"date-parts":[[2016,9,3]],"date-time":"2016-09-03T04:46:57Z","timestamp":1472878017000},"page":"74-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Evaluation of anticoagulation selection for acute venous thromboembolism"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7182-4347","authenticated-orcid":false,"given":"Hisham","family":"Badreldin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Rimsans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,3]]},"reference":[{"issue":"3","key":"1417_CR1","first-page":"505","volume":"102","author":"G Piazza","year":"2009","unstructured":"Piazza G et al (2009) Venous thromboembolic events in hospitalised medical patients. Thromb Haemost 102(3):505\u2013510","journal-title":"Thromb Haemost"},{"key":"1417_CR2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11239-006-5572-y","volume":"21","author":"JA Heit","year":"2006","unstructured":"Heit JA (2006) The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis 21:23\u201329","journal-title":"J Thromb Thrombolysis"},{"issue":"23 Suppl 1","key":"1417_CR3","first-page":"I4","volume":"107","author":"RH White","year":"2003","unstructured":"White RH (2003) The epidemiology of venous thromboembolism. Circulation 107(23 Suppl 1):I4\u2013I8","journal-title":"Circulation"},{"issue":"9828","key":"1417_CR4","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(11)61904-1","volume":"379","author":"SZ Goldhaber","year":"2012","unstructured":"Goldhaber SZ, Bounameaux H (2012) Pulmonary embolism and deep vein thrombosis. The Lancet 379(9828):1835\u20131846","journal-title":"The Lancet"},{"issue":"4","key":"1417_CR5","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/clpt.2011.185","volume":"90","author":"JA Johnson","year":"2011","unstructured":"Johnson JA et al (2011) Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 90(4):625\u2013629","journal-title":"Clin Pharmacol Ther"},{"issue":"7P2","key":"1417_CR6","doi-asserted-by":"crossref","first-page":"62S","DOI":"10.1592\/phco.24.10.62S.36120","volume":"24","author":"D Hawkins","year":"2004","unstructured":"Hawkins D (2004) Limitations of traditional anticoagulants. Pharmacotherapy 24(7P2):62S\u201365S","journal-title":"Pharmacotherapy"},{"issue":"3","key":"1417_CR7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1517\/13543784.16.3.271","volume":"16","author":"JI Weitz","year":"2007","unstructured":"Weitz JI, Linkins LA (2007) Beyond heparin and warfarin: the new generation of anticoagulants. Expert Opin Investig Drugs 16(3):271\u2013282","journal-title":"Expert Opin Investig Drugs"},{"key":"1417_CR8","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1182\/asheducation-2013.1.464","volume":"2013","author":"KA Bauer","year":"2013","unstructured":"Bauer KA (2013) Pros and cons of new oral anticoagulants. Hematol Am Soc Hematol Educ Program 2013:464\u2013470. doi: 10.1182\/asheducation-2013.1.464","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"6","key":"1417_CR9","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1177\/1060028016632785","volume":"50","author":"SW Finks","year":"2016","unstructured":"Finks SW, Trujillo TC, Dobesh PP (2016) Management of venous thromboembolism: recent advances in oral anticoagulation therapy. Ann Pharmacother 50(6):486\u2013501","journal-title":"Ann Pharmacother"},{"issue":"4","key":"1417_CR10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","volume":"78","author":"D Kubitza","year":"2005","unstructured":"Kubitza D et al (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78(4):412\u2013421","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"1417_CR11","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799\u2013808","journal-title":"N Engl J Med"},{"issue":"26","key":"1417_CR12","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"R Bauersachs","year":"2010","unstructured":"Bauersachs R et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499\u20132510","journal-title":"N Engl J Med"},{"issue":"14","key":"1417_CR13","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"HR Buller","year":"2012","unstructured":"Buller HR et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287\u20131297","journal-title":"N Engl J Med"},{"issue":"15","key":"1417_CR14","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"HR Buller","year":"2013","unstructured":"Buller HR et al (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406\u20131415","journal-title":"N Engl J Med"},{"issue":"24","key":"1417_CR15","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342\u20132352","journal-title":"N Engl J Med"},{"issue":"2","key":"1417_CR16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149(2):315\u2013352","journal-title":"Chest"},{"issue":"2","key":"1417_CR17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0889-8588(05)70349-X","volume":"10","author":"KB Green","year":"1996","unstructured":"Green KB, Silverstein RL (1996) Hypercoagulability in cancer. Hematol Oncol Clin North Am 10(2):499\u2013530","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"1417_CR18","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/00001721-199401000-00004","volume":"5","author":"A Falanga","year":"1994","unstructured":"Falanga A et al (1994) The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions. Blood Coagul Fibrinolysis 5 (Suppl 1):S19\u2013S23, (discussion 59\u201364)","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"12","key":"1417_CR19","doi-asserted-by":"crossref","first-page":"e114445","DOI":"10.1371\/journal.pone.0114445","volume":"9","author":"TB Larsen","year":"2014","unstructured":"Larsen TB et al (2014) Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS One 9(12):e114445","journal-title":"PLoS One"},{"issue":"7","key":"1417_CR20","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/jth.12605","volume":"12","author":"T Hulle Van der","year":"2014","unstructured":"Van der Hulle T et al (2014) Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost 12(7):1116\u20131120","journal-title":"J Thromb Haemost"},{"issue":"2","key":"1417_CR21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146\u2013153","journal-title":"N Engl J Med"},{"issue":"3","key":"1417_CR22","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0035-1549090","volume":"41","author":"G Cervellin","year":"2015","unstructured":"Cervellin G et al (2015) Quality and safety issues of direct oral anticoagulants in the emergency department. Semin Thromb Hemost 41(3):348\u2013354","journal-title":"Semin Thromb Hemost"},{"key":"1417_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/mej.0000000000000400","author":"K Hogg","year":"2016","unstructured":"Hogg K et al (2016) Direct oral anticoagulants: a practical guide for the emergency physician. Eur J Emerg Med. doi: 10.1097\/mej.0000000000000400","journal-title":"Eur J Emerg Med"},{"issue":"6","key":"1417_CR24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3111\/13696998.2015.1007210","volume":"18","author":"A Amin","year":"2015","unstructured":"Amin A et al (2015) Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. J Med Econ 18(6):399\u2013409","journal-title":"J Med Econ"},{"issue":"9","key":"1417_CR25","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3111\/13696998.2013.826664","volume":"16","author":"S Deitelzweig","year":"2013","unstructured":"Deitelzweig S et al (2013) Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients \u226575 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials. J Med Econ 16(9):1163\u20131168","journal-title":"J Med Econ"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-016-1417-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-016-1417-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-016-1417-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-016-1417-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T17:58:56Z","timestamp":1498327136000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-016-1417-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,3]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["1417"],"URL":"https:\/\/doi.org\/10.1007\/s11239-016-1417-5","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,3]]}}}